Is Metastatic Prostate Cancer Always Associated with High PSA?
No, metastatic prostate cancer is not always associated with high PSA levels, though this represents an uncommon but clinically important presentation that requires heightened diagnostic vigilance.
The Typical Presentation
The vast majority of metastatic prostate cancer cases do present with elevated PSA levels. Traditional imaging for metastatic disease (bone scans) is generally unnecessary when PSA is below specific thresholds because the yield is so low 1:
- Bone scan positivity is <5% even with PSA levels between 40-45 ng/mL after radical prostatectomy 1
- Most patients with positive bone scans have very high PSA (mean 61.3 ng/mL) and high PSA velocity (>0.5 ng/mL per month) 1
- Bone scans are generally unnecessary with clinically localized prostate cancer when PSA is <20 ng/mL 1
The Critical Exception: Low or Undetectable PSA with Metastases
Progression to metastatic disease can occur despite undetectable or low PSA levels, occurring in approximately 22% of certain high-risk populations 2. This phenomenon has several key characteristics:
High-Risk Features Predicting PSA-Discordant Metastases
Patients who develop metastases with low/undetectable PSA typically have 2:
- 85% have Gleason scores ≥7
- 63% have clinical T3 or T4 tumors
- 41% have pretreatment PSA >10 ng/mL
- 46% have atypical histologic variants (ductal, sarcomatoid, or small cell features)
Small Cell/Neuroendocrine Differentiation
This is the most important cause of metastatic disease with low PSA 1, 2:
- Small cell/neuroendocrine prostate cancer is present in 17% of metastatic castration-resistant prostate cancer (mCRPC) patients who undergo metastatic biopsies 1
- These tumors are characterized by low PSA levels despite large metastatic burden and visceral disease 1
- In one series, 8 of 10 patients (80%) who progressed with undetectable PSA had small cell carcinoma 2
- Patients with initial Grade Group 5 are especially at risk 1
Clinical Implications and Surveillance Strategy
When to Suspect PSA-Discordant Metastases
Maintain high clinical suspicion in patients with 2:
- High-grade, locally advanced tumors at diagnosis
- Atypical histologic variants on pathology
- Unexplained skeletal lesions or symptoms
- Clinical deterioration despite stable/low PSA
Recommended Surveillance Approach
For high-risk patients, complete physical evaluation and imaging studies may be indicated regardless of PSA level 2:
- In the study of PSA-discordant metastases, 67% of patients were asymptomatic at the time metastasis was detected 2
- Detection occurred only because of routine imaging studies 2
- 41% of patients progressed to metastasis without any increase in PSA from nadir level 2
Diagnostic Workup for Suspected Small Cell/Neuroendocrine Features
Biopsy of accessible metastatic lesions is recommended in patients with mCRPC to identify small cell/neuroendocrine histomorphologic features 1, particularly when:
- Disease no longer responds to androgen deprivation therapy (ADT)
- Low PSA despite metastatic burden
- Visceral metastases present
- Initial Grade Group 5 disease
Common Pitfalls to Avoid
Do not rely solely on PSA for surveillance in high-risk patients with Gleason ≥7, T3-4 disease, or atypical histology 2
Do not assume absence of metastases based on low PSA alone in patients with aggressive features 3, 2
Consider advanced imaging and biopsy when clinical picture doesn't match PSA levels, especially with unexplained symptoms or skeletal findings 3, 2
Recognize that PSA can be normal or minimally elevated even in stage IV disease, particularly with poorly differentiated or neuroendocrine variants 3, 4, 5